Goldman Sachs Asset Management has launched AlphaAI, an artificial intelligence investment platform focused on generating returns from the AI space, Reuters reported based on an internal memo of the company.

Lou D’Ambrosio will lead the platform as chairman of Artificial Intelligence for Asset Management, the report cited the memo as saying.

“We believe AI is ‌both reshaping ⁠industries and ⁠acting as a force multiplier in how we invest,” Marc Nachmann, global head of Goldman’s asset and wealth management division, said as per the report.

D’Ambrosio founded and led the Value Accelerator in 2018, chairs the firm’s AI Investing Leadership Council, and has previously served as chief executive of both private and publicly traded companies.

He told Reuters that they expect “AI to drive greater dispersion within sectors, not just across them”, and this wasn’t necessarily reflected in the prices. AlphaAI has been designed to identify this, drawing on insights from Goldman’s public and private markets businesses and more than 100 AI applications already operating at scale within its portfolio companies.

Darius Adamczyk will take over as global head of the Value Accelerator, a Goldman Sachs unit he previously co-led.
Exchange-traded funds targeting artificial intelligence are rapidly gaining ground, despite continued uncertainty over which companies will ultimately dominate the evolving technology landscape.US-domiciled mutual funds and ETFs with an AI-focused investment strategy collectively oversee $40.5 billion in assets, the report said citing Morningstar data.

The Defiance Quantum ETF is among the largest funds in the sector, managing $4.88 billion in assets invested across quantum computing, machine learning and related enabling technologies, it said.

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)

Glen Akselrod
Bristol Capital Ltd.

[Technical Difficulty] 2026 financial results conference call. Joining me on the call today are Randy Boomhour, President and Chief Executive Officer; Marie-Josee Cantin, Chief Financial Officer and Jordan Wolfe, President of MixOnSite. After management’s formal remarks, we’ll conduct a Q&A session. We’ll take covering analyst questions live via the online stream to the webinar portal and all other questions through the Q&A text box if you could see in the bottom portion of your Zoom window.

Before we begin, I’d like to remind everyone that today’s call and the accompanying presentation contain forward-looking information within the meaning of the applicable securities laws. These statements reflect management’s current expectations and assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those we discuss today. The complete forward-looking statement disclaimer is set out on the slide now displayed and the presentation is also available on our website at cematrix.com.

For a full description of the associated risks and assumptions, please refer to our 2025 management’s discussion and analysis and other filings available on SEDAR. We undertake no obligation to update these statements, except as required by law. Today’s discussion also includes certain non-GAAP measures, which are defined and reconciled in our MD&A.

With that, I’ll turn over the call to Randy. Randy, please go ahead.

Randy Boomhour
COO, CEO & President

Thank you, Glen. Very much appreciate the introduction there. We’re going to go through our entire deck. The

Microsoft’s shares soared more than 15% on Thursday, putting the company on track for a record one-day gain in market value after it said it expects to keep generating cash through its new fiscal year and forecast cloud growth above Wall Street expectations.

The software giant reportedly added more ⁠than $485 billion to ⁠its market value to reach $3.35 trillion, surpassing chip giant Nvidia’s previous one-day record of $441 billion on April 9, 2025, according to LSEG data.

“Microsoft reported a very strong quarter and it struck the tone markets are looking to hear as the key drivers of growth came from the cloud and AI divisions,” said Brian Mulberry, chief market strategist at Zacks Investment ⁠Management.

The company ‌has lagged some of its “Magnificent Seven” peers this year; its stock was down more than 18%, up to ⁠Wednesday’s close.

At least nine brokerages raised the target price on the stock, with the mean target now $560.90.

The results offered fresh evidence that Microsoft’s massive AI investments are beginning to pay off, helping ease investor concerns that heavy spending on data centers and computing infrastructure could outpace demand.
The company said its spending plans remain unchanged and that it expects capital expenditures of $50 billion ‌for the fiscal first quarter of 2027 and $175 billion for the 2026 calendar year.In its first quarter, Microsoft expects a 45% growth on a constant ⁠currency basis for its Azure cloud computing unit, well above analyst estimates of 40.92%, according to data from Visible Alpha.

“The key question was whether it could shift the conversation from how much it is spending on AI to what it is earning from those investments, and the results suggested meaningful progress,” Direxion’s head of capital markets, Jake Behan, said.

On Wall Street Week, Steven Rattner discussed how more affordable Chinese AI models could significantly alter the competitive landscape. These cheaper models may challenge established players, drive innovation, and influence market dynamics globally. Their adoption could democratize AI development and deployment, potentially shifting economic power and technological leadership towards China in the AI industry.

---

The emergence of cheaper Chinese AI models signals a potential shift in the global AI race. China’s advancements in artificial intelligence have been rapidly progressing, driven by government backing and a large tech ecosystem. Affordable AI solutions from Chinese companies could democratize access to sophisticated technologies, enabling startups and smaller nations to compete more effectively on the world stage.

These cost-effective Chinese models might challenge established Western tech giants, pushing innovation and reducing the dominance of expensive, proprietary AI systems. As the price barrier lowers, more organizations can deploy AI tools across various industries, from healthcare to automotive manufacturing, accelerating technological adoption worldwide.

However, concerns about data privacy, ethics, and geopolitical tensions may shape the impact of these cheaper Chinese models. While they could spur healthy competition and innovation, international cooperation and regulation will be vital to ensure safe and equitable AI development as the global landscape evolves.

source

Other People are Reading

Greggs’s pivot towards healthier products and trending drinks has helped it boost sales, with the bakery chain reporting a 20% rise in profit over the first half of the year.

Greggs, the UK’s largest fast-food chain, has launched a range of new products this year, many of which latch onto trends such as high-protein salads and matcha.

Greggs’s chief executive Roisin Currie previously told BBC News the rise of weight-loss drugs has led customers to to look for “smaller portions”, which could affect its bottom line.

Total sales for the bakery topped £1.1 billion for the 26 weeks to the end of June – 7.2% higher than the same period a year ago.

Pre-tax profit for the first half of the year was £76.0m – up from £63.5m for the first six months of 2025.

Currie said the company was “broadening and innovating our menu in line with changing tastes and trends”.

The company relaunched its salad range in May, “adding protein and increased choice for customers”.

It is also trying to appeal to “new and younger customers” through its new iced matcha lattes, and to health-conscious consumers by making nutritional information on its labels clearer.

Greggs, which has more UK outlets than McDonald’s, opened 34 stores in the first half of 2026. That brings the total to 2,773, taking into account 31 store closures.

More than half of the new openings were in areas with no Greggs stores within a mile. A similar proportion opened away from the High Street in locations including petrol forecourts, supermarkets, retail parks, hospitals and university campuses, it said.

Currie said Greggs is monitoring customer behaviour to ensure new stores boost visits “without cannibalising existing shop sales”.

She also said Greggs had no price rises planned after its breakfast, lunch and “big” deals went up in May, following multiple hikes last year.

“Our prices are in a good place and we will now be working hard to protect the consumer and making sure that we can offer that value throughout the rest of the year,” she said.

A daily multivitamin may offer modest but measurable benefits for older adults’ cardiovascular health and their ability to perform everyday activities, according to new research presented this week at the annual meeting of the American Society for Nutrition.

The initial findings, which have not yet been published in a peer-reviewed medical journal, showed that older adults who took a daily multivitamin had significantly better measures of functional health after three years compared with those who took a placebo. Yanbin Dong, a cardiologist and director of the Georgia Prevention Institute at the Medical College of Georgia at Augusta University, led the research. “The findings show that a daily multivitamin may be a simple, low-risk strategy to help older adults maintain cardiovascular-related functional health and quality of life,” Dong said.

The study drew on data from more than 16,000 individuals ages 60 and older who did not have major cardiovascular disease at the study’s outset. Participants were randomly assigned to take a daily multivitamin, a cocoa extract supplement, both, or a placebo, with placebo pills used for the control group as well as for participants taking only one of the two active supplements.

Researchers tracked participants’ health over three years using an annual questionnaire that assessed both their ability to complete everyday tasks and possible symptoms of heart failure, including fatigue, shortness of breath, and swelling of the legs, ankles, feet or abdomen. The questionnaire uses a scale from 0 to 100, with lower scores indicating greater symptom burden and worse overall health status.

After three years, researchers found that participants taking multivitamins showed an average improvement of 0.45 points in symptom burden and 0.30 points in their overall clinical summary score, a combined measure averaging symptom burden with physical ability, according to Dong.

The benefit appeared substantially more pronounced among a specific subgroup of participants: those with carotid stenosis, a narrowing of the major blood vessels in the neck that supply blood to the brain. Among this group, symptom burden improved by an average of 6.75 points, while clinical summary scores improved by 6.01 points, considerably larger effects than those observed across the broader study population. “This means those who had a history of carotid stenosis and took multivitamin minerals will have a small clinical benefit of improving cardiovascular and functional health over time,” Dong said.

Dong said the underlying mechanism likely involves multivitamins correcting common micronutrient shortfalls that can otherwise go unaddressed through diet alone, potentially supporting energy production, cellular function, vascular health, inflammation control and muscle performance.

The study’s authors also examined the effects of cocoa extract supplementation separately. While cocoa extract did not produce a statistically significant change in functional health scores across the overall study population, it did show a meaningful benefit specifically among participants who went on to develop congestive heart failure during the study period, consistent with prior research suggesting that anti-inflammatory compounds found in cocoa extract may offer some degree of heart-protective effect.

Sarah Booth, director of the Human Nutrition Research Center on Aging at Tufts University, who was not involved in the new research, cautioned that the broader scientific record on multivitamin supplementation remains mixed. Booth noted that earlier analyses using data from the same overall participant pool had found no significant association between daily multivitamin or cocoa extract use and reduced risk of cardiovascular disease or cancer more broadly, even as other research has separately suggested multivitamins may provide a modest cognitive benefit. Booth said a fuller interpretation of the newest findings will not be possible until the complete study is formally published.

Booth also pointed to a persistent challenge in interpreting multivitamin research: participants’ underlying diets vary widely and are rarely controlled for in these kinds of trials. “Individuals still consume their usual food during these studies, so the multivitamins are adding more nutrients into the diet above and beyond the usual nutrient intake,” Booth said. “If the participants are already consuming a healthy diet, then adding more nutrients is unlikely to improve that individual’s health trajectory. Those who routinely take multivitamins tend to be individuals with healthier diets, which sometimes contributes to mixed results we see in the randomized clinical trials.”

The study’s authors pointed to its large participant population and high rate of sustained multivitamin adherence over several years as key strengths. They also acknowledged limitations, noting that most participants in the trial were, in Dong’s words, “very healthy” at the study’s outset, meaning the evidence for benefits among people already at higher risk for heart problems remains more limited. The researchers disclosed that Mars, a major chocolate manufacturer, supported the cocoa extract portion of the study, while Pfizer and Haleon, a British consumer healthcare company, provided the multivitamins used in the trial, though the researchers said none of the sponsors had any role in the study’s design, analysis or interpretation of results.

Booth emphasized that good nutrition should generally begin with a healthy diet built around whole foods rather than supplements, though she acknowledged that some people are unable to consistently achieve that on their own. She cautioned against self-diagnosing nutrient deficiencies simply because supplements are readily available over the counter. “Decisions to take multivitamins ideally should be in consultation with one’s health provider,” Booth said.

Given that this research involves a specific population of older adults and touches on cardiovascular health, anyone considering starting a daily multivitamin, particularly those with existing heart conditions or other chronic health concerns, is encouraged to speak with a doctor or healthcare provider before beginning any new supplement regimen, rather than relying solely on preliminary research findings that have not yet undergone full peer review.

Chipotle CEO Scott Boatwright said Wednesday the fast-casual chain is seeing improvement in customers’ perceptions of affordability.

Speaking on Chipotle’s second-quarter earnings call, Boatwright said the company’s brand tracking showed improved perceptions of value across “all income groups and age cohorts.”

“As it relates to value, I’m happy to report our brand tracker showed really solid progress across all income groups and age cohorts on value perception,” Boatwright said. “Our affordability scores were better in Q2 than they’ve been in probably the past couple of years.”

He noted that customers do not judge value solely by prices or discounts.

CHIPOTLE OPENS FIRST RESTAURANT IN MEXICO AS GLOBAL EXPANSION ACCELERATES

“And so I think we’re making meaningful progress as it relates to value at Chipotle. What we also learned, I think, as an important note, is [that] value isn’t just about discounting and price point. It’s about convenience. It’s about execution,” Boatwright added. 

“It’s about menu innovation. There’s a host of things that the consumer is looking at to determine value.”

Chipotle has recently introduced lower-priced menu options.

CHIPOTLE CEO ALLEGEDLY SUGGESTS COMPANY WOULD KEEP RAISING PRICES AND ‘LEAN INTO’ CUSTOMERS MAKING OVER $100K

In December, the company launched a high-protein menu featuring a Single Chicken Taco, starting at $3.50 at select U.S. restaurants, and a High Protein Cup of Adobo Chicken, with a national weighted average price of $3.82, the company said at the time.

Chipotle on Wednesday also reported second-quarter revenue of $3.3 billion, up 9.3% from the same period in 2025.

Boatwright has previously pushed back against perceptions that Chipotle has become too expensive or reduced its portions to boost profits.

Ticker	Security	Last	Change	Change %
CMG	CHIPOTLE MEXICAN GRILL INC.	38.53	+4.29	+12.53%

CHIPOTLE RIVAL GUZMAN Y GOMEZ MEXICAN KITCHEN CLOSES ALL US RESTAURANTS

“We have an affordable price point for all walks of life, and we’re for everyone. We want everyone to have access to wholesome, nutritious food,” Boatwright said during a May appearance on Yahoo Finance’s “Power Players” podcast.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Wall Street ended sharply higher on Thursday, with chip stocks jumping and Microsoft soaring after the technology giant gave a stellar forecast that eased fears about massive spending on AI infrastructure.

Microsoft jumped by a double-digit percentage after the technology company forecast quarterly sales and cloud growth above expectations. It also reported capital expenditures below estimates and said it expects to keep generating cash through its fiscal 2027 that has just begun.

This year, investors ‌have been spooked ⁠by heavy ⁠spending on AI at big technology firms. Negative cash-flow reports from Alphabet and Tesla last week sparked a bout of selling in AI-linked stocks, with chip stocks also under pressure as investors questioned high valuations.

Meta Platforms tumbled after the social media heavyweight reported a 91% drop in second-quarter free cash flow, indicating the financial strain of its costly AI buildout.

“These are true battleground stocks. Investors can’t make up their minds whether the ROI on the massive capex spending is going to be worthwhile or not,” said Jed Ellerbroek, portfolio manager at Argent Capital Management.

“Microsoft delivered yesterday, and maybe Microsoft is going to be able to move itself from the ‘battleground’ camp to be a ‘trusted AI winner’ ⁠stock,” Ellerbroek said.
The ‌PHLX chip index surged,with Micron Technology Sandisk and Advanced Micro Devices making big gains. Amazon rose and Apple dipped, with both companies set to report their results after the market closes.

Amazon’s stock has underperformed the broader market this year due to ⁠concerns about heavy spending on AI. Apple, which has not spent heavily on AI, recently overtook Nvidia to become the world’s most valuable company, with a market value of about $4.9 trillion.

On Wednesday, U.S. stocks closed sharply lower after the Federal Reserve left interest rates unchanged, with mixed messages from new Fed Chair Kevin Warsh leaving traders confused about the path of borrowing costs.

Bond markets remained on edge, with the yield on the 30-year Treasury bond surging to its highest level in 19 years.

Traders are now ‌only pricing in a 59% chance for a rate hike at the Fed’s September meeting, according to CME FedWatch, down from 82% a week ago.

U.S. economic growth slowed in the second quarter as the trade deficit widened. The economy grew at a 1.5% rate, slower than estimates of ⁠2.1% growth, data showed. A separate reading also showed U.S. inflation slowed in June.

Qualcomm fell after the chipmaker forecast fourth-quarter profit below estimates and said revenue from Apple products would decline faster than expected.

Fair Isaac slumped. Even though the credit-scoring giant lifted its annual profit and revenue forecasts, they remained below analysts’ estimates.

Starbucks rose after the world’s largest coffee chain raised its annual sales and profit forecasts.

Analysts on average expect S&P 500 aggregate second-quarter earnings to jump 40% from a year ago, with AI-related stocks accounting for much of that growth, according to LSEG I/B/E/S.

Strong earnings forecasts and a recent decline in share prices have left the S&P 500 trading at about 20 times expected earnings, just above its 10-year average of 19, according to LSEG data.

The Penarth headquartered firm has released a trading statement to the City

Penarth headquartered global point of care diagnostics firm EKF Diagnostics said it is on track for a stronger end to the year after posting first half numbers in line with management expectations, while confirming that cash levels held in Russia have risen.

In a trading statement the Alternative Investment Market listed firm that in the first half of this year revenues remained broadly flat at £25.m (H1 2025: £25.2m), reflecting the higher weighting of sales expected in the second half of the year. Gross margin improved to 53% (H1 2025: 50%) and adjusted Ebitda showed continued growth.

The group’s cash balance as at 30 June 2026 was £16 (31 December 2025: £15.8m), which included £2.4m held in Russia (31 December 2025: £2.1m).

It operates in Russia via its German-based subsidiary, in which it has a 60% stake, selling non sanctioned medical devices. However, since Russia’s invasion of Ukraine the Putin administration has put tight limits on the amount of cash from trading that foreign firms are able to move out of the country.

It is a counter measure to western sanctions. For the last two years EKF’s subsidiary has been able to release around £500,000 per annum in dividend payments. The rise in cash from £2.1m to £2.5m has in part been driven by improved exchange rates.

EKF has no bank borrowings, and the closing cash balance reflects the allocation of £1.4m for the ongoing share buyback programme, of which £900,000 has been deployed during the period, together with the continued investment for growth that is part of the five-year strategic development plan for the business.

It said: “The progress of the five-year strategy continues in line with management expectations. Diabetes and hematology delivered steady performances in the first half, with the majority of high-volume tenders already won and scheduled to be delivered in the historically stronger second half year.”

It added that its remains on track to deliver growth at the revenue and adjusted Ebitda levels for full year 2026 in line with current market expectations.

Following the trading statement brokers Singer, Stifel and Panmure Liberum all maintained their buy share positions. Panmure Liberum has a share price target of 34p with the other two slightly higher at 35p.

In its note Panmure Liberum said: “The shares are still cheap, and remain range bound with he buy-back providing a floor to the price.

“There is little in the statement to change this prior to the interims. However, the longer-term outlook remains more encouraging and we expect the growth rate to improve, margins to continue to expand and strong cash conversion. We retain our buy (share recommendation).

Shares in EKF fell slightly after the trading statement to around 25p.